Advertisement
Advertisement
AVXL
Anavex Life Sciences
2.35
USDSponsored
-0.12
-4.86%
Sep 23, 15:58 UTC -4
Closed
After-Market
2.35
0.00
-0.21%
AVXL Earnings Reports
Positive Surprise Ratio
AVXL beat 27 of 39 last estimates.
69%
Next Report
Date of Next Report
Nov 23, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.11
Implied change from Q3 26 (Revenue/ EPS)
--
/+37.50%
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Anavex Life Sciences earnings per share and revenue
On Aug 25, 2026, AVXL reported earnings of -0.08 USD per share (EPS) for Q3 26, beating the estimate of -0.08 USD, resulting in a 1.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +14.47% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 5 analysts forecast an EPS of -0.11 USD, with revenue projected to reach -- USD, implying an increase of 37.50% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Anavex Life Sciences's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Anavex Life Sciences reported EPS of -$0.08, beating estimates by 1.96%, and revenue of $0.00, 0% as expectations.
How did the market react to Anavex Life Sciences's Q3 2026 earnings?
The stock price moved up 14.47%, changed from $3.11 before the earnings release to $3.56 the day after.
When is Anavex Life Sciences expected to report next?
The next earning report is scheduled for Nov 23, 2026.
What are the forecasts for Anavex Life Sciences's next earnings report?
Based on 5
analysts, Anavex Life Sciences is expected to report EPS of -$0.11 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.